The shrinking renal replacement therapy 'break-even' point

Transplantation

Volumn 66, Issue 12, 1998, Pages 1702-1708

  Schweitzer, Eugene J ^a,b   Wiland, Anne ^a   Evans, Debora ^a   Novak, Melvin ^a   Connerny, Ingrid ^a   Norris, Lisa ^a   Colonna, John O ^a   Philosophe, Benjamin ^a   Farney, Alan C ^a   Jarrell, Bruce E ^a   Bartlett, Stephen T ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; AGED; ARTICLE; COST CONTROL; DIALYSIS; FEMALE; GRAFT SURVIVAL; HEALTH CARE COST; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; ORGAN DONOR; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; FEMALE; GRAFT REJECTION; HOSPITAL CHARGES; HUMANS; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; MEDICARE; MIDDLE AGED; PATIENT READMISSION; RENAL DIALYSIS; UNITED STATES;

EID: 0032573690     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00023     Document Type: Article

References (27)

1. U.S. Renal Data System. Chapter II. Incidence and prevalence of ESRD. In: USRDS 1996 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, 1997.
2. 1995 Annual Report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network -Transplant Data: 1988-1994. UNOS, Richmond, VA, and the Division of Transplantation, Bureau of Health Resources Development, Health Resources and Services Administration, US Department of Health and Human Services, Rockville, MD.
3. Schweitzer EJ, Yoon S, Hart J, et al. Increased living donor volunteer rates with a formal recipient family education program. Am J Kidney Dis 1997; 29(5): 739.
4. Flowers JL, Jacobs S, Cho E, et al. Comparison of open and laparoscopic live donor nephrectomy. Ann Surg 1997; 226(4): 483.
5. Cosimi AB. The donor and donor nephrectomy. In: Morris PJ, ed. Kidney transplantation: principles and practice, 4th ed. Philadelphia, PA: Saunders, 1994: 56-70.
6. Briggs JD. The recipient of a renal transplant. In: Morris PJ, ed. Kidney transplantation: principles and practice, 4th ed. Philadelphia, PA: Saunders, 1994: 45-55.
7. Schweitzer EJ, Yoon S, Fink J, et al. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation 1998; 65(2): 242.
8. Schweitzer EJ, Drachenberg CB, Anderson L, et al. Significance of the Banff borderline biopsy. Am J Kidney Dis 1996; 28(4): 585.
9. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
10. Eggers PW. Cost issues in transplantation. Surg Clin North Am 1994; 74(5): 1259.
11. Hauboldt RH. Cost implications of human organ and tissue transplantations, an update: 1996. Available at: http://www2. milliman.com/milliman/publications/reports/HRR16/default. html. Accessed April 2, 1998.
12. Eggers P. Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 1992; 12(3): 284.
13. U.S. Renal Data System. Chapter EX. The economic cost of ESRD and Medicare spending for alternative modalities of treatment. In: USRDS 1996 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, 1997.
14. Port FK, Wolft RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270(11): 1339.
15. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235.
16. Cecka MJ. Living donor transplants. In: Cecka MJ, Terasaki PI, eds. Clinical transplants 1995. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1996: 363-377.
17. Eggers PW. Effect of transplantation on the Medicare end stage renal disease program. N Engl J Med 1988; 318: 223.
18. Pastan S, Bailey JB. Dialysis therapy. N Engl J Med 1998; 338(20): 1428.
19. Day LM. From fee-for-service to capitation: factors driving ESRD reimbursement system changes. Nephrol News Issues 1997; 11(4): 22.
20. Coutts LR, Neumann ME. The stage is set for disease management and ESRD: can it succeed? Nephrol News Issues 1998; 12(5 Suppl): 8.
21. United States Renal Data System. USRDS 1997 Annual Data Report. X. The economic cost of ESRD, vascular access procedures, and Medicare spending for alternative modalities of treatment. Am J Kidney Dis 1997; 30(2): S160.
22. Cohen DJ, Benvenisty AI, Cianci J, Hardy MA. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function. Am J Kidney Dis 1989; 14(5 Suppl 2): 19.
23. Norman DJ, Kahana L, Stuart FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55(1): 44.
24. Mozes MF, Venkat KK, Kupin W, et al. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation? Transplant Proc 1993; 25(1): 575.
25. Shaffer D, Madras PN, Conway P, Davis C, Simpson MA, Monaco AP. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants. Transplant Proc 1997; 29: 342.
26. Shield CF, Jacobs EJ, Wyant S, Das A. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am J Kidney Dis 1996; 27(6): 855.
27. Gorman KJ, Fein AJ, Shield CF. Relationship between clinical outcome, inpatient length of stay, and cost of renal transplantation at four US transplant centers. Transplant Proc 1993; 25(1): 1690.